Screener
Denali Therapeutics Inc. DNLI Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s total liabilities?
- Denali Therapeutics Inc. (DNLI) reported total liabilities of $322.78M in Q2 2026.
- How has Denali Therapeutics Inc.'s total liabilities changed year-over-year?
- Denali Therapeutics Inc.'s total liabilities increased by 131.9% year-over-year, from $139.19M to $322.78M.
- What is the long-term trend for Denali Therapeutics Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total liabilities has grown at a 553.5% compound annual growth rate (CAGR), from $11K to $131.09M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Denali Therapeutics Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude